NASDAQ: LHDX

Lucira Health, Inc.

Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Lucira Health, Inc. (NASDAQ: LHDX) resulting from allegations that Lucira may have issued materially misleading business information to the investing public.

If you purchased Lucira securities and would like to join the prospective action, please click “Join This Class Action.”

If you purchased Lucira securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Contact Us

Details of investigation:

On October 8, 2021, pre-market, Lucira issued a press release reporting that its supply partner Copan Italia SPA announced a recall of its FLOQSwabs included in the LUCIRA COVID-19 All-In-One Test Kit and LUCIRA CHECK IT COVID-19 Test Kit. The press release stated that “[a]ccording to Lucira’s records, Test Kits containing the recalled Copan swabs were distributed from April 22, 2021 through September 22, 2021,” and that the recalled Copan swabs should not be used and should be disposed.

On this news, Lucira’s stock price dropped sharply during intraday trading on October 8, 2021, damaging investors.

关注我们:
公司名称: Lucira Health, Inc.
股票代号: LHDX
集体诉讼期: N/A
法院: N/A

The Rosen Law Firm has been ranked among the top 4 law firms each year since 2013 for the number of successful securities class actions on behalf of investors. In 2019 alone, our firm recovered $438 million for investors.

投资者应仔细鉴别和遴选在引领证券集体诉讼方面有多年成功经验的的律师。通常,其他律所会发布关于集体诉讼的新闻稿,但却没有类似的经验或资源。

机构股东服务公司按 2017 年证券集体诉讼索赔数量,罗森律师事务所列为第一名。

The Rosen Law Firm represents investors throughout the globe. Our mission is to prosecute securities fraud class actions and protect shareholders’ rights.

Rosenlegal
滚动至顶部